<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Telogen effluvium</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Telogen effluvium</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Telogen effluvium</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wilma Bergfeld, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maria Hordinsky, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1164291204"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Telogen effluvium is a form of diffuse, nonscarring hair loss that presents as a transient or chronic loss of hair  (<a class="graphic graphic_picture graphicRef129221 graphicRef129222 graphicRef105345" href="/z/d/graphic/129221.html" rel="external">picture 1A-C</a>). Hair loss in telogen effluvium occurs as a result of an abnormal shift in follicular cycling that leads to the premature shedding of hair. (See  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Hair cycle'</a>.)</p><p>A wide variety of endogenous and exogenous factors have been linked to the induction of telogen effluvium. Examples include major surgery, serious illness, childbirth, protein or caloric malnutrition, drugs, and severe emotional distress. In some cases, the inciting cause is unclear or multiple inciting triggers are identified.</p><p>The clinical features, diagnosis, and management of telogen effluvium will be reviewed here. An overview of the evaluation of patients with scalp hair loss is provided separately. (See  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss"</a>.)</p><p class="headingAnchor" id="H1164291211"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Data on the epidemiology of telogen effluvium are limited. The disorder is one of the most common forms of nonscarring hair loss for which patients present for clinical evaluation [<a href="#rid1">1</a>]. Telogen effluvium does not appear to have a predilection for particular racial or ethnic groups.</p><p>Most experts divide telogen effluvium into acute and chronic variants:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute telogen effluvium</strong> – Acute telogen effluvium may occur at any age, including infants and children [<a href="#rid2">2,3</a>]. For unclear reasons, women are more likely to present for evaluation of acute telogen effluvium than men [<a href="#rid4">4</a>]. (See <a class="local">'Clinical features'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic telogen effluvium</strong> – Chronic telogen effluvium is much less common than the acute variant and is most frequently diagnosed in women between the ages of 30 and 60 years [<a href="#rid5">5,6</a>]. Chronic telogen effluvium can be further subdivided into chronic and chronic-repetitive clinical presentations. (See <a class="local">'Clinical features'</a> below.)</p><p></p><p class="headingAnchor" id="H1164291218"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The excessive hair shedding that characterizes telogen effluvium occurs as a result of altered regulation of the hair follicle growth cycle:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normal hair cycle</strong> – Normally, each follicle on the human scalp cycles independently through three major phases: anagen (growth), catagen (transformation), and telogen (rest). The end of the three-month telogen phase is marked by the shedding of hair from the follicle [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Hair cycle'</a>.)</p><p></p><p class="bulletIndent1">The asynchronous cycling of scalp hair follicles in humans prevents periodic episodes of mass shedding of hair. Rather, shedding of hair occurs on a continuous basis. In the absence of scalp or hair disorders, 50 to 150 hairs are typically shed each day [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hair cycle changes in telogen effluvium</strong> – Telogen effluvium occurs when the proportion of hair follicles in the telogen phase increases significantly, resulting in subsequent prominent shedding of hair. On the normal human scalp, only approximately 10 percent of follicles are in the telogen phase at any given time, while anagen and catagen follicles account for approximately 90 and &lt;1 percent of follicles, respectively [<a href="#rid8">8</a>]. In telogen effluvium, it is estimated that 7 to 35 percent of the follicles that normally would have remained in the anagen phase shift into the telogen phase [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Proposed mechanisms for telogen hair loss</strong> – The mechanism of hair loss in telogen effluvium is not completely understood. It is generally accepted that an identifiable or occult, physiologic event stimulates a change in follicular cycling due to an insult to the anagen bulb (one of the two hair growth centers).</p><p></p><p class="bulletIndent1">Several theories of the mechanism of hair loss have been proposed, some of which have been associated with specific stimuli for telogen effluvium [<a href="#rid10">10</a>]. Immediate anagen release and delayed anagen release are the most commonly cited theories: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immediate anagen release </strong>– Immediate anagen release may be a common mechanism for telogen effluvium. According to this theory, a significant proportion of anagen follicles are stimulated to enter telogen prematurely. Immediate anagen release may be the primary mechanism for telogen effluvium related to physiologic stress (eg, high fever) or drugs [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Delayed anagen release </strong>– The theory of delayed anagen release describes prolongation of the duration of anagen, thereby delaying the onset of telogen. Hair loss is noted once the stimulus for sustaining anagen ends and the affected follicles enter telogen and, subsequently, shed. Delayed anagen release may be the primary mechanism for postpartum telogen effluvium [<a href="#rid10">10,11</a>].</p><p></p><p class="bulletIndent1">Additional theories for the mechanism of telogen effluvium have been proposed [<a href="#rid10">10,12</a>]. Abnormal shortening of the anagen phase could contribute to an increase in hair shedding by augmenting the proportion of follicles in the telogen phase. In addition, shortening of the telogen phase could lead to the simultaneous release of hair from a large proportion of telogen follicles (immediate telogen release). Reduced variance in the duration of anagen has been proposed as a mechanism of chronic telogen effluvium [<a href="#rid12">12</a>]. Last, a delay in telogen release could lead to an increase in hair shedding due to the sudden release of hairs from follicles that were stimulated to remain in the telogen phase for an extended period. Delayed telogen release may account for seasonal fur shedding in mammals.</p><p></p><p class="headingAnchor" id="H1164291225"><span class="h1">INCITING FACTORS</span><span class="headingEndMark"> — </span>A wide variety of factors have been associated with the induction of telogen effluvium based upon clinical observations. However, data to confirm and define the level of risk for telogen effluvium related to these factors are lacking.</p><p>It is estimated that in approximately one-third of patients with acute telogen effluvium, an inciting factor cannot be identified [<a href="#rid4">4</a>]. The cause of chronic telogen effluvium is usually more difficult to identify, but careful history taking can be helpful. (See <a class="local">'Diagnosis'</a> below.)</p><p>Potential inciting factors for telogen effluvium include:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute or chronic major illness (eg, systemic rheumatic disease [collagen vascular disease] [<a href="#rid13">13</a>], febrile illness, major surgery)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Childbirth (telogen gravidarum)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Significant emotional stress</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nutritional changes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Rapid weight loss</p><p class="bulletIndent2"><span class="glyph">•</span>Protein or caloric dietary restriction</p><p class="bulletIndent2"><span class="glyph">•</span>Nutritional deficiencies (eg, iron deficiency anemia, congenital or acquired zinc deficiency, vitamin D)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endocrine disorders (eg, hypothyroidism, hyperthyroidism, androgen excess)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drugs, supplements, or toxins (eg, heavy metals [<a href="#rid14">14</a>])  (<a class="graphic graphic_table graphicRef91674" href="/z/d/graphic/91674.html" rel="external">table 1</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inflammatory conditions of the scalp (eg, seborrheic dermatitis, psoriasis)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infectious conditions that affect the scalp (eg, fungal, bacterial, viral, or spirochetal)</p><p></p><p>Lower serum vitamin D and serum ferritin (iron storage) levels have been proposed as contributors to telogen effluvium; however, data are insufficient to confirm a causative relationship. Observational studies have suggested a correlation between low serum levels of vitamin D and telogen effluvium [<a href="#rid15">15-18</a>]. Vitamin D receptors are found in epidermal keratinocytes and mesodermal dermal papilla cells and are postulated to play an important role in hair follicle cycling [<a href="#rid19">19</a>]. Studies evaluating the relationship between serum ferritin levels and telogen effluvium have yielded conflicting results [<a href="#rid15">15,16,20-28</a>].</p><p class="headingAnchor" id="H1164291232"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>The major clinical finding in telogen effluvium is an acute or chronic reduction in scalp hair density  (<a class="graphic graphic_picture graphicRef129221 graphicRef129222 graphicRef105345" href="/z/d/graphic/129221.html" rel="external">picture 1A-C</a>). Less than 50 percent of scalp hair is typically lost. Therefore, progression to complete balding does not occur [<a href="#rid5">5</a>].</p><p>Because only a portion of the hair is lost, the severity of hair loss may not be readily apparent in patients with a history of voluminous hair prior to the onset of telogen effluvium. In such cases, the patient history and viewing of prior photographs may provide the clinician with a clearer idea of the change in hair density.</p><p>The progression of telogen effluvium typically follows one of two courses  (<a class="graphic graphic_figure graphicRef91675" href="/z/d/graphic/91675.html" rel="external">figure 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute telogen effluvium </strong>– Telogen hair loss develops within two to three months after the inciting factor and reverses once the inciting factor is eliminated. The time for clinically relevant hair regrowth is between 6 to 12 months since length of hair is important for the perception of regrowth.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic telogen effluvium </strong>– An idiopathic condition in which telogen hair loss persists for <strong>more than</strong> four to six months. Some patients develop a chronic-repetitive pattern of telogen effluvium that is punctuated by serial episodes of acute hair loss as a result of multiple intermittent triggers. </p><p></p><p>The distribution of scalp hair loss in telogen effluvium is typically diffuse; however, hair loss may be most noticeable in the bitemporal  (<a class="graphic graphic_picture graphicRef129222 graphicRef76636" href="/z/d/graphic/129222.html" rel="external">picture 1B, 1D</a>), frontal, and vertex areas [<a href="#rid5">5</a>]. A patchy or "moth-eaten" pattern of hair loss is often evident in syphilis-related telogen effluvium  (<a class="graphic graphic_picture graphicRef122663 graphicRef122662" href="/z/d/graphic/122663.html" rel="external">picture 2A-B</a>).</p><p>In the absence of a concomitant hair or scalp disorder, the scalp and hair shafts appear normal, with normal variation in hair shaft diameters, and symptoms are absent. In addition to the scalp, telogen effluvium may affect other hair-bearing areas [<a href="#rid9">9,29</a>].</p><p>Hair loss due to telogen effluvium may lead to the recognition of a pre-existing hair loss disorder that was not as obvious previously. For example, this may occur in patients with early-stage male or female androgenetic alopecia or central centrifugal cicatricial alopecia. (See  <a class="medical medical_review" href="/z/d/html/83783.html" rel="external">"Male pattern hair loss (androgenetic alopecia in males): Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/15679.html" rel="external">"Female pattern hair loss (androgenetic alopecia in females): Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/15681.html" rel="external">"Central centrifugal cicatricial alopecia"</a>.)</p><p class="headingAnchor" id="H91936450"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>An increased proportion of telogen follicles is the key histopathologic finding [<a href="#rid30">30</a>]. Unlike androgenetic alopecia, the proportion of vellus or indeterminate hair follicles is not increased [<a href="#rid6">6</a>]. Therefore, variation in hair shaft diameters is much less than that observed in androgenetic alopecia.</p><p>In the absence of co-occurring inflammatory disorder of the scalp, scalp biopsies from patients with telogen effluvium do not demonstrate inflammation. Biopsies taken from patients with telogen effluvium induced by inflammation in the scalp will demonstrate an increased proportion of telogen follicles as well as histopathologic findings consistent with the inciting inflammatory disorder. As an example, biopsies of syphilitic alopecia usually demonstrate characteristic lymphoplasmacytic, perivascular, and perifollicular infiltrates [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/13669.html" rel="external">"Seborrheic dermatitis in adolescents and adults", section on 'Histopathology'</a>.)</p><p class="headingAnchor" id="H1164291246"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The recognition of diffuse, noninflammatory, nonscarring hair loss should raise clinical suspicion for telogen effluvium, particularly when it occurs acutely and is preceded by a physiologic or psychologic stressor.</p><p>A diagnosis of acute telogen effluvium can usually be made based upon the patient history, physical examination, and a hair pull test. Scalp biopsies are helpful for evaluating patients in whom the diagnosis is unclear and as a component of the diagnostic evaluation of hair loss in patients with findings suggestive of chronic telogen effluvium. (See <a class="local">'Clinical features'</a> above.)</p><p class="headingAnchor" id="H91936318"><span class="h2">Patient history</span><span class="headingEndMark"> — </span>The patient history is of great value in the evaluation of the patient with suspected telogen effluvium. A thorough patient history confirms a course of hair loss consistent with telogen effluvium, may reveal the underlying cause(s) of telogen effluvium, and is useful for ruling out other causes of hair loss. In older adult patients or other patients with multiple medical disorders, the cause of telogen effluvium may be multifactorial. (See <a class="local">'Inciting factors'</a> above and  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss"</a>.)</p><p>Key inquiries include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Course of hair loss</strong> (date of onset, duration, apparent triggers)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Characteristics of hair loss</strong> (estimated amount of hair lost daily, appearance of lost hair shafts [intact versus broken hairs])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medical history</strong> (see <a class="local">'Inciting factors'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recent or chronic medical illness </p><p class="bulletIndent2"><span class="glyph">•</span>Major surgeries</p><p class="bulletIndent2"><span class="glyph">•</span>Rapid weight loss</p><p class="bulletIndent2"><span class="glyph">•</span>Restricted diets</p><p class="bulletIndent2"><span class="glyph">•</span>Recent childbirth, miscarriage, or abortion</p><p class="bulletIndent2"><span class="glyph">•</span>Iron deficiency anemia</p><p class="bulletIndent2"><span class="glyph">•</span>Nutritional deficiency (ie, zinc, protein, iron, ferritin, vitamin D)</p><p class="bulletIndent2"><span class="glyph">•</span>Thyroid disorder</p><p class="bulletIndent2"><span class="glyph">•</span>Review of systems to identify unknown underlying disorders</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychologic stressors</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug and nutritional supplement history</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>History of toxic exposure</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Family history of hair disease(s)</strong></p><p></p><p>In addition, the patient history may provide clues that a different (or concomitant) hair loss disorder is present. Inquiring about the menstrual and reproductive history of women may lead to consideration of the possibility of androgenetic alopecia due to androgen excess or conditions such as polycystic ovarian syndrome (PCOS). Similarly, a careful family history may elucidate information that raises suspicion for a heritable hair loss disorder, such as androgenetic alopecia, which may lead to increased shedding associated with shortening of the anagen phase. (See  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Inherited and acquired structural hair disorders'</a>.)</p><p class="headingAnchor" id="H1164291253"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Patients should receive a careful examination of the scalp skin, scalp hair, and nails (see  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Physical examination'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scalp</strong> – The entire skin surface of the scalp should be examined to identify the extent of hair loss and to detect features of other hair or scalp disorders. Scale, inflammation, pustules, and scarring (evidenced by loss of follicular ostia or a bound-down appearance of skin) are not features of isolated telogen effluvium. The detection of such findings suggests the presence of a different (or concomitant) scalp disorder. As an example, greasy scale and erythema on the scalp suggests the possibility of seborrheic dermatitis, a common disorder associated with telogen effluvium and androgenetic alopecia. (See <a class="local">'Inciting factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hair shafts</strong> – Abnormalities of the hair shaft are also not features of telogen effluvium. If many broken hairs are visualized in a patient with a complaint of hair loss, the clinician should consider the possibility of heat- or chemical-related damage to the hair shaft, trichotillomania, or a structural hair disorder. (See  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Scalp and hair examination'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nails</strong> – Examination of the nails should be performed and may offer clues to the cause of telogen effluvium. As examples, Beau lines in the nails suggest the recent occurrence of a significant medical illness  (<a class="graphic graphic_picture graphicRef78502 graphicRef85706" href="/z/d/graphic/78502.html" rel="external">picture 3A-B</a>), and patients with iron deficiency anemia may demonstrate koilonychia (nail "spooning"  (<a class="graphic graphic_picture graphicRef86419" href="/z/d/graphic/86419.html" rel="external">picture 4</a>)). (See  <a class="medical medical_review" href="/z/d/html/13682.html" rel="external">"Overview of nail disorders", section on 'Nail signs of systemic diseases'</a>.)</p><p></p><p class="headingAnchor" id="H91936369"><span class="h3">Hair pull test</span><span class="headingEndMark"> — </span>A hair pull test should be performed on multiple sites of the scalp as part of the physical examination in patients who present with clinical findings suggestive of telogen effluvium. The test aids in the recognition of active hair shedding and the identification of telogen hair loss. A hair pull test will be negative in patients in whom hair shedding secondary to telogen effluvium has ceased.</p><p>The procedure is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Grasp 50 to 60 hair fibers close to the skin surface.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gently tug the hairs from the proximal to distal ends.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Repeat the hair pull in several areas of the scalp (eg, right parietal, left parietal, and frontal scalp).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Examine the hair shafts with a light microscope to confirm that the loose hairs are telogen hairs  (<a class="graphic graphic_picture graphicRef50528" href="/z/d/graphic/50528.html" rel="external">picture 5</a>). Examination of the proximal portion of the hair can identify a telogen bulb. Other features, such as dystrophic anagen bulb or trichorrhexis nodosum, suggest the presence of other hair disorders. (See  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Microscopic examination'</a> and  <a class="medical medical_review" href="/z/d/html/110102.html" rel="external">"Hair shaft disorders"</a>.)</p><p></p><p>The extraction of five or more telogen hair fibers in a single pull or more than 15 telogen hairs in three pulls is consistent with active telogen effluvium.</p><p>Of note, a false-negative hair pull test can occur if the patient has shampooed or vigorously groomed the hair on the day of examination. The test is best performed two to three days after shampooing. Conversely, a false-positive hair pull test may be noted if the patient has not shampooed or combed the hair for several days.</p><p class="headingAnchor" id="H936504"><span class="h3">Dermoscopy</span><span class="headingEndMark"> — </span>Data on dermoscopic findings in telogen effluvium are limited. Acute telogen effluvium may demonstrate empty follicles and many upright regrowing hairs of normal thickness (&gt;0.06 to 0.09 mm)  (<a class="graphic graphic_picture graphicRef114974" href="/z/d/graphic/114974.html" rel="external">picture 6</a>). </p><p>Dermoscopic findings may help to distinguish chronic telogen effluvium from female pattern hair loss (female androgenetic alopecia). The latter exhibits greater hair diameter variability [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H1157813"><span class="h3">Wood's light examination</span><span class="headingEndMark"> — </span>Examination with a Wood's light (a source of ultraviolet A light) can be helpful for detecting findings of seborrheic dermatitis, a condition that has been associated with telogen effluvium. A Wood's lamp can also facilitate detection of hyperpigmentation, a finding more strongly associated with chronic cicatricial (scarring) alopecias than telogen effluvium. (See  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Cicatricial alopecia'</a>.)</p><p>In seborrheic dermatitis, the Wood's lamp can highlight the presence of scale that is not easily seen with visible light. In addition, <em>Malassezia</em> yeasts, which are thought to play a role in seborrheic dermatitis, fluoresce orange upon exposure to ultraviolet light [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H3322294820"><span class="h2">Scalp biopsy</span><span class="headingEndMark"> — </span>Scalp biopsies are primarily reserved for patients in whom the diagnosis is uncertain or who exhibit features suggestive of chronic telogen effluvium (eg, persistence of shedding for at least four to six months) because it can be difficult to clinically distinguish chronic telogen effluvium from diffuse presentations of alopecia areata and female pattern hair loss. (See <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/z/d/html/15679.html" rel="external">"Female pattern hair loss (androgenetic alopecia in females): Pathogenesis, clinical features, and diagnosis", section on 'Scalp biopsy'</a> and  <a class="medical medical_review" href="/z/d/html/3320.html" rel="external">"Alopecia areata: Clinical manifestations and diagnosis", section on 'Histopathology'</a>.)</p><p>Scalp biopsies are typically performed as 4 mm punch biopsies that extend into the subcutaneous fat. Many dermatopathologists prefer to receive two punch biopsies (one sectioned horizontally, one sectioned vertically) rather than a single biopsy because this allows for the evaluation of the tissue in both vertical and horizontal sections. (See  <a class="medical medical_review" href="/z/d/html/5577.html" rel="external">"Skin biopsy techniques", section on 'Punch biopsy'</a>.) </p><p>The preferred site for biopsy is an area outside sites of predilection for androgenetic alopecia to reduce the possibility of diagnostic confusion; thus, when feasible, it is helpful to avoid the bitemporal, frontal, and vertex areas of the scalp. The preferred site is the leading edge of an affected area of hair thinning (but not a bald area) on the scalp. If there is no obvious leading edge of hair thinning, biopsies may be taken from the parietal scalp. Examination of the biopsy specimens by a dermatopathologist experienced in the evaluation of hair and scalp disorders is ideal. (See <a class="local">'Histopathology'</a> above and  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Scalp biopsies'</a> and  <a class="medical medical_review" href="/z/d/html/5577.html" rel="external">"Skin biopsy techniques", section on 'Punch biopsy'</a>.)</p><p class="headingAnchor" id="H3608985890"><span class="h2">Additional tests</span><span class="headingEndMark"> — </span>Less common methods for evaluating telogen effluvium primarily utilized in specialized hair centers and research studies include trichograms, phototrichograms, and hair collections:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trichograms and phototrichograms</strong> – Trichograms and phototrichograms are evaluation techniques that provide an assessment of the proportion of telogen and anagen hair follicles/hairs on the scalp. These procedures are described in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Trichograms and phototrichograms'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hair collections</strong> – Hair collections can be useful for quantifying the amount of hair that is being lost as well as following the course of telogen effluvium. To perform a hair collection, the patient is instructed to collect hair that sheds during morning hair grooming each day for two weeks. These collections are packaged in separate envelopes or other containers and labeled with the date and an "S" for the shampoo days. Hair loss of greater than 100 to 150 hairs per day is consistent with an effluvium. The collected hairs can be examined under a microscope to confirm that they are telogen hairs. This collection can be repeated at intervals to determine improvement or worsening of the telogen effluvium.</p><p></p><p class="headingAnchor" id="H1164291260"><span class="h1">EVALUATION FOR CAUSE</span><span class="headingEndMark"> — </span>When the patient history and physical examination fail to identify a clear trigger for telogen effluvium, testing to search for a contributing factor is typically performed. There are no laboratory tests that definitively diagnose telogen effluvium. (See <a class="local">'Inciting factors'</a> above.)</p><p>The author typically obtains the following tests:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count with red blood cell indices (to assess for anemia)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Complete metabolic panel (to assess for signs of underlying disease) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid-stimulating hormone (to assess for a thyroid disorder) (see  <a class="medical medical_review" href="/z/d/html/7891.html" rel="external">"Laboratory assessment of thyroid function", section on 'Evaluating for thyroid dysfunction'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ferritin (to assess iron storage) (see  <a class="medical medical_review" href="/z/d/html/7150.html" rel="external">"Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Iron studies (list of available tests)'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>25-hydroxyvitamin D levels (to assess for vitamin D deficiency) [<a href="#rid17">17,34</a>]</p><p></p><p>The selection of additional laboratory studies is guided by the need to rule out disorders in the differential diagnosis or to further investigate patients with signs or symptoms suggestive of a particular underlying disease, nutritional deficiency, heavy metal or other toxin exposure, or other causes of hair loss. As examples, a hormonal work-up to rule out hair loss related to hyperandrogenemia would be appropriate in women with signs of virilization, acne, and obesity, and further evaluation with antinuclear antibodies (ANAs) or other studies would be appropriate for a patient with signs or symptoms of an underlying autoimmune disease. In addition, dietary history may reveal nutritional deficiencies that should be evaluated.</p><p class="headingAnchor" id="H1164291267"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>A variety of nonscarring hair and scalp disorders share clinical features with telogen effluvium:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anagen effluvium </strong>– Anagen effluvium is an acute loss of anagen hair fibers secondary to chemotherapy or toxin exposure and represents acute loss of greater than 80 percent of the scalp hair. Exclamation point hairs (short, 1 to 3 mm hairs with a tapered base) that result from dystrophic hair growth are a common finding. Microscopic evaluation of the proximal ends of hairs dislodged during a hair pull test demonstrates normal or dystrophic anagen hairs rather than telogen hairs. (See  <a class="medical medical_review" href="/z/d/html/1156.html" rel="external">"Alopecia related to systemic cancer therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Androgenetic alopecia (male or female pattern hair loss)</strong> – Features of androgenetic alopecia that are useful for distinguishing this condition from telogen effluvium include a clinical examination that demonstrates a characteristic pattern of hair loss and miniaturized hairs  (<a class="graphic graphic_picture graphicRef83802 graphicRef83804 graphicRef87195" href="/z/d/graphic/83802.html" rel="external">picture 7A-C</a>). A biopsy can be useful for differentiating between these diagnoses in difficult cases. Of note, the two conditions may coexist, and telogen hair shedding can occur early in the course of androgenetic alopecia. (See  <a class="medical medical_review" href="/z/d/html/83783.html" rel="external">"Male pattern hair loss (androgenetic alopecia in males): Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/15679.html" rel="external">"Female pattern hair loss (androgenetic alopecia in females): Pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diffuse alopecia areata </strong>– Diffuse alopecia areata is an uncommon form of alopecia areata that is characterized by the diffuse loss of scalp hair, resulting in the appearance of generalized hair thinning  (<a class="graphic graphic_picture graphicRef87197" href="/z/d/graphic/87197.html" rel="external">picture 8</a>). Similar to anagen effluvium, exclamation point hairs may be present, and performance of the hair pull test may reveal dystrophic anagen hairs. A biopsy revealing an inflammatory infiltrate consistent with alopecia areata differentiates this condition from telogen effluvium. (See  <a class="medical medical_review" href="/z/d/html/3320.html" rel="external">"Alopecia areata: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Loose anagen syndrome </strong>– Loose anagen syndrome is a rare, nonscarring hair loss disorder that manifests with easily extracted anagen hairs from the scalp  (<a class="graphic graphic_picture graphicRef87472" href="/z/d/graphic/87472.html" rel="external">picture 9</a>). Young children are typically affected, particularly females with blond hair. Characteristically, examination of shed hairs reveals anagen hairs with ruffled cuticles  (<a class="graphic graphic_picture graphicRef87514" href="/z/d/graphic/87514.html" rel="external">picture 10</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Structural hair disorders </strong>– A variety of structural hair disorders causes weakening of the hair shaft that results in easily fractured hair. Unlike telogen effluvium, in which hair is shed from the follicle, these conditions result in increased breakage of hair. Close examination and 2x magnification of the loose hair will reveal broken hairs and may also reveal characteristic findings of a particular structural hair disorder. (See  <a class="medical medical_review" href="/z/d/html/110102.html" rel="external">"Hair shaft disorders"</a>.)</p><p></p><p class="headingAnchor" id="H1164291311"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Telogen effluvium is usually a reactive and reversible disorder but may be the heralding event of underlying medical disorders or an adverse effect of treatments. Therefore, identifying and correcting the underlying cause is the most important component of patient management. Psychologic support, techniques for camouflaging hair loss, and clinical follow-up are useful adjuncts for managing the psychosocial effects of hair loss. (See <a class="local">'Psychologic support'</a> below and <a class="local">'Cosmetic measures'</a> below and <a class="local">'Follow-up'</a> below.)</p><p class="headingAnchor" id="H91936491"><span class="h2">Removal or treatment of underlying cause</span><span class="headingEndMark"> — </span>Although spontaneous improvement is expected for patients with telogen effluvium related to an isolated event (eg, childbirth), patients with telogen effluvium related to a persisting insult should have the cause eliminated or treated when feasible. </p><p>Examples of interventions include:</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment for associated illness</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rectification for dietary deficiency</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Discontinuation of suspect drug (cease suspected drug for at least three months prior to reassessment of shedding)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of concomitant hair or scalp disorders (eg, seborrheic dermatitis)</p><p></p><p class="headingAnchor" id="H20017313"><span class="h2">Psychologic support</span><span class="headingEndMark"> — </span>Hair loss can have a profound psychosocial impact, which may seem out of proportion to the degree of hair loss [<a href="#rid35">35,36</a>]. Thus, consideration of the patient's emotional well-being is an important component of patient management. </p><p>Measures that may be helpful include:</p><p class="bulletIndent1"><span class="glyph">●</span>Addressing the patient's concerns in a sensitive manner.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Providing a basic explanation of the hair growth cycle and its relationship to telogen effluvium, such as communication of the following points:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Normally, individual scalp hairs are in different phases of the hair cycle (growing, resting, or shedding). The growing phase is the longest (three to seven years). The resting and shedding phase is shorter (approximately three to four months). In the normal scalp, the majority of hairs are in the growing phase.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In telogen effluvium, something triggers many hair follicles that are in the growing phase to prematurely enter the resting phase, which results in shedding up to 30 percent of the scalp hair. The amount of hair lost depends upon the impact of the inciting cause of telogen effluvium on the hair follicles.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the cause of hair loss is discovered and either eliminated or treated, the hair loss resolves and regrowth becomes noticeable over 6 to 12 months.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complete loss of scalp hair is not expected.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Providing a follow-up visit. Follow-up evaluations can be helpful for reassuring patients as well as for identifying patients who require further evaluation because of persistent telogen effluvium. (See <a class="local">'Follow-up'</a> below.)</p><p></p><p class="headingAnchor" id="H1592578619"><span class="h2">Cosmetic measures</span><span class="headingEndMark"> — </span>Consultation with a cosmetologist can help patients identify measures that minimize the cosmetic effects of hair loss. Hair styling techniques, hair coloring, scalp camouflage, and hair prostheses can be useful for camouflaging hair loss. Hair transplantation is <strong>not</strong> indicated for patients with telogen effluvium.</p><p class="headingAnchor" id="H91936586"><span class="h2">Interventions with uncertain efficacy</span><span class="headingEndMark"> — </span>The efficacy of treatments, such as topical <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> and nutritional supplementation in the absence of nutrient deficiency, on telogen effluvium is unclear.</p><p>Our approach to supplementation involves correction of diagnosed nutrient deficiencies and iron supplementation for patients with ferritin levels beneath a certain threshold. (See <a class="local">'Iron supplementation in the absence of iron deficiency anemia'</a> below.)</p><p class="headingAnchor" id="H91936564"><span class="h3">Topical minoxidil</span><span class="headingEndMark"> — </span>Some clinicians utilize topical <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a>, a drug primarily used for the treatment of male and female androgenetic alopecia, for chronic telogen effluvium, despite insufficient evidence to confirm efficacy. The drug is prescribed in an attempt to maintain hair density and stimulate regrowth of hair. Most experts believe that minoxidil is not helpful for telogen effluvium that is expected to resolve spontaneously or has an inciting cause that can be eliminated [<a href="#rid37">37</a>]. Others, including the author, opt to start minoxidil when shedding begins in an attempt to support hair regrowth.</p><p>In androgenetic alopecia, <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> promotes hair growth by prolonging anagen, shortening telogen and kenogen, and enlarging miniaturized hair follicles. The efficacy of topical minoxidil in telogen effluvium has not been evaluated in clinical studies. (See  <a class="medical medical_review" href="/z/d/html/3321.html" rel="external">"Male pattern hair loss (androgenetic alopecia in males): Management", section on 'Topical minoxidil'</a>.)</p><p>A typical regimen involves the application of topical 5% <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> once daily to the entire scalp. Twice-daily application of minoxidil 2% is an alternative.</p><p>Beneficial effects of <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> on hair maintenance and growth are not expected to be evident immediately; a full year of use is considered necessary to assess efficacy. In patients with chronic telogen effluvium, clinical experience suggests that continued use may be necessary to maintain benefit.</p><p>Of note, occasionally, increased hair shedding can occur within the first two to eight weeks of treatment in patients treated with topical <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> for androgenetic alopecia. This is thought to result from the release of hairs from telogen follicles as they are stimulated by minoxidil to transition from telogen to anagen [<a href="#rid1">1,38</a>]. A telogen effluvium frequently follows the cessation of topical minoxidil in patients with androgenetic alopecia [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H1787391603"><span class="h3">Oral minoxidil</span><span class="headingEndMark"> — </span>Although small, retrospective studies have suggested improvement in telogen effluvium during treatment with low-dose oral <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a>, additional study is necessary to determine whether oral minoxidil is an effective treatment [<a href="#rid40">40-42</a>]. In one retrospective study of 36 female patients with chronic telogen effluvium (increased telogen hair shedding for &gt;6 months), treatment with oral minoxidil (0.25 to 2.5 mg per day) was associated with a reduction in hair shedding scores [<a href="#rid40">40</a>]. Additional study is necessary to determine whether oral minoxidil is an effective treatment.</p><p>Examples of potential adverse effects of oral <a class="drug drug_general" data-topicid="9655" href="/z/d/drug information/9655.html" rel="external">minoxidil</a> include hypertrichosis, postural hypotension, and edema [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H1457827161"><span class="h3">Iron supplementation in the absence of iron deficiency anemia</span><span class="headingEndMark"> — </span>Although it is accepted that patients with iron deficiency anemia should receive iron supplementation, iron supplementation for the treatment of telogen effluvium in the absence of iron deficiency or iron storage anemia is controversial. Additional studies are necessary to clarify whether iron supplementation is beneficial for nonanemic patients with telogen effluvium.</p><p>Supplementing iron intake to reach ferritin levels greater than 30, 40, or 70 mcg/L in patients with hair loss has been recommended by some experts based upon a belief that treatment for hair loss is optimized at greater serum ferritin levels [<a href="#rid1">1,22,26,44</a>]. In one small, placebo-controlled, randomized trial of 12 women with chronic telogen effluvium who were treated with iron and lysine supplements (n = 5) or placebo (n = 7) for six months, a 31 percent reduction in the proportion of hairs in the telogen phase was detected in the treatment group compared with a 9 percent increase in the proportion of telogen hairs in the placebo group [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/z/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults"</a>.)</p><p>The uncertainty regarding the impact of iron supplementation on telogen effluvium has contributed to disagreement among experts about the need for iron supplementation and the target for the ferritin level when iron therapy is given. Based upon personal clinical experience that suggests benefit, the author routinely prescribes dietary modification or oral iron supplementation for patients with telogen effluvium to obtain and maintain serum levels of ferritin well within the reference range of the assay used at her institution (at least 70 mcg/L). Of note, ferritin reference ranges are assay specific. </p><p class="headingAnchor" id="H3279977802"><span class="h3">Other supplements</span><span class="headingEndMark"> — </span>The impact of supplements such as zinc (in the absence of symptomatic zinc deficiency), <a class="drug drug_general" data-topicid="120386" href="/z/d/drug information/120386.html" rel="external">biotin</a>, and vitamin D on telogen effluvium is unclear. Although correction of identified nutritional deficiencies is advised, the effects of correction on the course of telogen effluvium are unconfirmed. Benefit of these supplements in the absence of nutritional deficiency is also unconfirmed.</p><p class="headingAnchor" id="H3139905871"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>Arranging clinical follow-up six months after the initial visit is useful. This visit provides helpful reassurance for patients with acute telogen effluvium that improves and allows for the identification of patients who require additional evaluation due to persistent or worsening telogen effluvium. (See <a class="local">'Prognosis'</a> below and <a class="local">'Evaluation for cause'</a> above.)</p><p>Photographs are less helpful in telogen effluvium than in androgenetic hair loss, alopecia areata, or primary scarring alopecia. However, standardized photographs of midline part, central, and occipital scalp at the time of diagnosis provide a baseline assessment and a frame of reference for future visits. Since hair grows 0.5 to 1 cm a month, photographic follow-up will also allow for assessment of regrowth [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H20017145"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The prognosis of telogen effluvium is dependent on the ability to remove or treat the inciting factor. If the underlying cause spontaneously resolves or can be eliminated, the course of telogen effluvium is self-limited.</p><p>Patients typically exhibit active shedding that persists for two to three months followed by stabilization and regrowth of hair. Cosmetically significant improvement is usually noted within 6 to 12 months. Telogen effluvium in which the underlying cause cannot be identified or removed may persist for years [<a href="#rid46">46</a>]. Complete baldness does not occur in acute or chronic telogen effluvium [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H625709879"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– Telogen effluvium is one of the most common forms of nonscarring hair loss for which patients present for clinical evaluation. Both children and adults may develop telogen effluvium. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis </strong>– Telogen effluvium results from an alteration in follicular cycling that leads to the excessive shedding of telogen hairs. A wide variety of endogenous and exogenous factors have been linked to induction of telogen effluvium. Examples include serious illness, major surgery, childbirth, rapid weight loss, nutritional deficiency, profound emotional stress, and drug exposure. The cause of telogen effluvium may be multifactorial in patients who have multiple medical problems or who are taking multiple drugs. In some cases, an inciting factor cannot be identified. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>– Hair loss in telogen effluvium manifests as a diffuse reduction in hair density  (<a class="graphic graphic_picture graphicRef129221 graphicRef129222 graphicRef105345" href="/z/d/graphic/129221.html" rel="external">picture 1A-C</a>). Less than 50 percent of the normal hair density is usually lost in telogen effluvium. Progression to complete balding does not occur (see <a class="local">'Clinical features'</a> above and <a class="local">'Prognosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute telogen effluvium </strong>– In most cases of telogen effluvium, the course is self-limited, with hair loss beginning two to three months after the inciting factor and reversing once the inciting factor resolves or is eliminated  (<a class="graphic graphic_figure graphicRef91675" href="/z/d/graphic/91675.html" rel="external">figure 1</a>). (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic telogen effluvium </strong>– Chronic telogen effluvium is a less common, idiopathic presentation of telogen effluvium that most commonly occurs in women between the ages of 30 and 60 years. Chronic telogen effluvium may persist for years  (<a class="graphic graphic_figure graphicRef91675" href="/z/d/graphic/91675.html" rel="external">figure 1</a>). (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– The diagnosis of telogen effluvium can usually be made based upon the patient history and physical examination. Laboratory testing may be helpful for identifying an etiology when the inciting factor for telogen effluvium is unknown. Scalp biopsies are typically reserved for patients in whom the diagnosis is uncertain and for patients with findings suggestive of chronic telogen effluvium (hair loss persisting for more than four to six months). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– The most important component of the management of patients with telogen effluvium is the identification and removal of the underlying cause. Data are insufficient to determine whether iron supplementation is beneficial in the absence of iron deficiency or iron storage anemia. (See <a class="local">'Management'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hordinsky MK. Medical treatment of noncicatricial alopecia. Semin Cutan Med Surg 2006; 25:51.</a></li><li><a class="nounderline abstract_t">Atton AV, Tunnessen WW Jr. Alopecia in children: the most common causes. Pediatr Rev 1990; 12:25.</a></li><li><a class="nounderline abstract_t">Nnoruka EN, Obiagboso I, Maduechesi C. Hair loss in children in South-East Nigeria: common and uncommon cases. Int J Dermatol 2007; 46 Suppl 1:18.</a></li><li><a class="nounderline abstract_t">Harrison S, Sinclair R. Telogen effluvium. Clin Exp Dermatol 2002; 27:389.</a></li><li><a class="nounderline abstract_t">Trüeb RM. Systematic approach to hair loss in women. J Dtsch Dermatol Ges 2010; 8:284.</a></li><li><a class="nounderline abstract_t">Whiting DA. Chronic telogen effluvium: increased scalp hair shedding in middle-aged women. J Am Acad Dermatol 1996; 35:899.</a></li><li><a class="nounderline abstract_t">Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med 1999; 341:491.</a></li><li><a class="nounderline abstract_t">Price VH. Treatment of hair loss. N Engl J Med 1999; 341:964.</a></li><li class="breakAll">Bergfeld WF. Telogen effluvium. In: Hair and Scalp Diseases: Medical, Surgical and Cosmetic Treatments, McMichael A, Hordinsky M (Eds), Informa Health Care, 2008. p.119.</li><li><a class="nounderline abstract_t">Headington JT. Telogen effluvium. New concepts and review. Arch Dermatol 1993; 129:356.</a></li><li><a class="nounderline abstract_t">Gizlenti S, Ekmekci TR. The changes in the hair cycle during gestation and the post-partum period. J Eur Acad Dermatol Venereol 2014; 28:878.</a></li><li><a class="nounderline abstract_t">Gilmore S, Sinclair R. Chronic telogen effluvium is due to a reduction in the variance of anagen duration. Australas J Dermatol 2010; 51:163.</a></li><li><a class="nounderline abstract_t">Cassano N, Amerio P, D'Ovidio R, Vena GA. Hair disorders associated with autoimmune connective tissue diseases. G Ital Dermatol Venereol 2014; 149:555.</a></li><li><a class="nounderline abstract_t">Yavuz IH, Yavuz GO, Bilgili SG, et al. Assessment of Heavy Metal and Trace Element Levels in Patients with Telogen Effluvium. Indian J Dermatol 2018; 63:246.</a></li><li><a class="nounderline abstract_t">Rasheed H, Mahgoub D, Hegazy R, et al. Serum ferritin and vitamin d in female hair loss: do they play a role? Skin Pharmacol Physiol 2013; 26:101.</a></li><li><a class="nounderline abstract_t">Cheung EJ, Sink JR, English Iii JC. Vitamin and Mineral Deficiencies in Patients With Telogen Effluvium: A Retrospective Cross-Sectional Study. J Drugs Dermatol 2016; 15:1235.</a></li><li><a class="nounderline abstract_t">Gerkowicz A, Chyl-Surdacka K, Krasowska D, Chodorowska G. The Role of Vitamin D in Non-Scarring Alopecia. Int J Mol Sci 2017; 18.</a></li><li><a class="nounderline abstract_t">Nayak K, Garg A, Mithra P, Manjrekar P. Serum Vitamin D3 Levels and Diffuse Hair Fall among the Student Population in South India: A Case-Control Study. Int J Trichology 2016; 8:160.</a></li><li><a class="nounderline abstract_t">Demay MB. The hair cycle and Vitamin D receptor. Arch Biochem Biophys 2012; 523:19.</a></li><li><a class="nounderline abstract_t">Avci A, Avci D, Ozyurt K. Laboratory findings of 563 women with telogen effluvium. Med J Bakirkoy 2015; 11:120.</a></li><li><a class="nounderline abstract_t">Poonia K, Thami GP, Bhalla M, et al. NonScarring Diffuse Hair Loss in Women: a Clinico-Etiological Study from tertiary care center in North-West India. J Cosmet Dermatol 2019; 18:401.</a></li><li><a class="nounderline abstract_t">Trost LB, Bergfeld WF, Calogeras E. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol 2006; 54:824.</a></li><li><a class="nounderline abstract_t">Olsen EA, Reed KB, Cacchio PB, Caudill L. Iron deficiency in female pattern hair loss, chronic telogen effluvium, and control groups. J Am Acad Dermatol 2010; 63:991.</a></li><li><a class="nounderline abstract_t">Kantor J, Kessler LJ, Brooks DG, Cotsarelis G. Decreased serum ferritin is associated with alopecia in women. J Invest Dermatol 2003; 121:985.</a></li><li><a class="nounderline abstract_t">Sinclair R. There is no clear association between low serum ferritin and chronic diffuse telogen hair loss. Br J Dermatol 2002; 147:982.</a></li><li><a class="nounderline abstract_t">Rushton DH. Nutritional factors and hair loss. Clin Exp Dermatol 2002; 27:396.</a></li><li><a class="nounderline abstract_t">Bregy A, Trueb RM. No association between serum ferritin levels &gt;10 microg/l and hair loss activity in women. Dermatology 2008; 217:1.</a></li><li><a class="nounderline abstract_t">Du X, She E, Gelbart T, et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science 2008; 320:1088.</a></li><li><a class="nounderline abstract_t">Bergfeld WF, Mulinari-Brenner F. Shedding: how to manage a common cause of hair loss. Cleve Clin J Med 2001; 68:256.</a></li><li class="breakAll">Weedon D. Diseases of cutaneous appendages. In: Weedon's Skin Pathology, 3rd ed, Elsevier, 2010. p.397.</li><li><a class="nounderline abstract_t">Jordaan HF, Louw M. The moth-eaten alopecia of secondary syphilis. A histopathological study of 12 patients. Am J Dermatopathol 1995; 17:158.</a></li><li><a class="nounderline abstract_t">Miteva M, Tosti A. Hair and scalp dermatoscopy. J Am Acad Dermatol 2012; 67:1040.</a></li><li><a class="nounderline abstract_t">Mayser P, Stapelkamp H, Krämer HJ, et al. Pityrialactone- a new fluorochrome from the tryptophan metabolism of Malassezia furfur. Antonie Van Leeuwenhoek 2003; 84:185.</a></li><li><a class="nounderline abstract_t">Sattar F, Almas U, Ibrahim NA, et al. Efficacy of Oral Vitamin D3 Therapy in Patients Suffering from Diffuse Hair Loss (Telogen Effluvium). J Nutr Sci Vitaminol (Tokyo) 2021; 67:68.</a></li><li><a class="nounderline abstract_t">Hadshiew IM, Foitzik K, Arck PC, Paus R. Burden of hair loss: stress and the underestimated psychosocial impact of telogen effluvium and androgenetic alopecia. J Invest Dermatol 2004; 123:455.</a></li><li><a class="nounderline abstract_t">Reid EE, Haley AC, Borovicka JH, et al. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. J Am Acad Dermatol 2012; 66:e97.</a></li><li><a class="nounderline abstract_t">Dauton A, Harries M. Chronic telogen effluvium: a systemic review of interventions. Br J Dermatol 2017; 177:52.</a></li><li><a class="nounderline abstract_t">Blumeyer A, Tosti A, Messenger A, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges 2011; 9 Suppl 6:S1.</a></li><li><a class="nounderline abstract_t">Tosti A, Iorizzo M, Vincenzi C. Finasteride treatment may not prevent telogen effluvium after minoxidil withdrawal. Arch Dermatol 2003; 139:1221.</a></li><li><a class="nounderline abstract_t">Perera E, Sinclair R. Treatment of chronic telogen effluvium with oral minoxidil: A retrospective study. F1000Res 2017; 6:1650.</a></li><li><a class="nounderline abstract_t">de Nicolas-Ruanes B, Moreno-Arrones OM, Saceda-Corralo D, et al. Low-dose oral minoxidil for treatment of androgenetic alopecia and telogen effluvium in a pediatric population: A descriptive study. J Am Acad Dermatol 2022; 87:700.</a></li><li><a class="nounderline abstract_t">Randolph M, Tosti A. Oral minoxidil treatment for hair loss: A review of efficacy and safety. J Am Acad Dermatol 2021; 84:737.</a></li><li><a class="nounderline abstract_t">Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. J Am Acad Dermatol 2021; 84:1644.</a></li><li><a class="nounderline abstract_t">Tosti A, Piraccini BM, Sisti A, Duque-Estrada B. Hair loss in women. Minerva Ginecol 2009; 61:445.</a></li><li><a class="nounderline abstract_t">BARMAN JM, ASTORE I, PECORARO V. THE NORMAL TRICHOGRAM OF THE ADULT. J Invest Dermatol 1965; 44:233.</a></li><li><a class="nounderline abstract_t">Sinclair R. Chronic telogen effluvium: a study of 5 patients over 7 years. J Am Acad Dermatol 2005; 52:12.</a></li></ol></div><div id="topicVersionRevision">Topic 15683 Version 10.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16616303" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Medical treatment of noncicatricial alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2194176" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Alopecia in children: the most common causes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17919200" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hair loss in children in South-East Nigeria: common and uncommon cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12190639" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Telogen effluvium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20105246" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Systematic approach to hair loss in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8959948" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Chronic telogen effluvium: increased scalp hair shedding in middle-aged women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10441606" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The biology of hair follicles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10498493" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Treatment of hair loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10498493" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Treatment of hair loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8447677" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Telogen effluvium. New concepts and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23682615" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The changes in the hair cycle during gestation and the post-partum period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20695853" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Chronic telogen effluvium is due to a reduction in the variance of anagen duration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24975949" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hair disorders associated with autoimmune connective tissue diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29937562" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Assessment of Heavy Metal and Trace Element Levels in Patients with Telogen Effluvium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23428658" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Serum ferritin and vitamin d in female hair loss: do they play a role?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27741341" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Vitamin and Mineral Deficiencies in Patients With Telogen Effluvium: A Retrospective Cross-Sectional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29215595" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The Role of Vitamin D in Non-Scarring Alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28442870" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Serum Vitamin D3 Levels and Diffuse Hair Fall among the Student Population in South India: A Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22008469" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The hair cycle and Vitamin D receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Laboratory findings of 563 women with telogen effluvium</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29774652" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : NonScarring Diffuse Hair Loss in Women: a Clinico-Etiological Study from tertiary care center in North-West India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16635664" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The diagnosis and treatment of iron deficiency and its potential relationship to hair loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20947203" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Iron deficiency in female pattern hair loss, chronic telogen effluvium, and control groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14708596" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Decreased serum ferritin is associated with alopecia in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12410711" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : There is no clear association between low serum ferritin and chronic diffuse telogen hair loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12190640" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Nutritional factors and hair loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18309237" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : No association between serum ferritin levels&gt;10 microg/l and hair loss activity in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18451267" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The serine protease TMPRSS6 is required to sense iron deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11263854" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Shedding: how to manage a common cause of hair loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11263854" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Shedding: how to manage a common cause of hair loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8600781" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The moth-eaten alopecia of secondary syphilis. A histopathological study of 12 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22405573" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hair and scalp dermatoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14574113" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pityrialactone- a new fluorochrome from the tryptophan metabolism of Malassezia furfur.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33642467" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Efficacy of Oral Vitamin D3 Therapy in Patients Suffering from Diffuse Hair Loss (Telogen Effluvium).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15304082" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Burden of hair loss: stress and the underestimated psychosocial impact of telogen effluvium and androgenetic alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21601948" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Chronic telogen effluvium: a systemic review of interventions</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21980982" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12975176" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Finasteride treatment may not prevent telogen effluvium after minoxidil withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29167734" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Treatment of chronic telogen effluvium with oral minoxidil: A retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35476919" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Low-dose oral minoxidil for treatment of androgenetic alopecia and telogen effluvium in a pediatric population: A descriptive study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32622136" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Oral minoxidil treatment for hair loss: A review of efficacy and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33639244" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19749676" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Hair loss in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14282465" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : THE NORMAL TRICHOGRAM OF THE ADULT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15692504" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Chronic telogen effluvium: a study of 5 patients over 7 years.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
